论文部分内容阅读
目的为探讨肺癌对耐药基因P170，GSTpi的表达情况和临床意义。方法应用S-P微波免疫组化法对43例肺癌进行了检测。结果显示肺癌中P170GSTpi总阳性表达率为51．1％及55．8％，其中SCLC（18．2％与27．3％）明显低于NSCDe（63．5％与65．85％），在NSCLC中癌瘤分化程度与P170，GSTpi的表达有正相关倾向，曾做化疗的肺癌中耐药基因的阳性率增高。结论研究结果说明，检测癌组织中P170，GSTpi对肺癌化疗有重要的指导意义，同时应强调肺癌的化疗应特别注意规范化。
Objective To investigate the expression and clinical significance of P170 and GSTpi in lung cancer. Methods 43 cases of lung cancer were detected by S-P microwave immunohistochemistry. The results showed that the total positive rate of P170GSTpi in lung cancer was 51.1% and 55.8%, of which SCLC (18.2% and 27.3%) was significantly lower than NSCDe (63.5% and 65.85%). There was a positive correlation between the degree of tumor differentiation in NSCLC and the expression of P170 and GSTpi. The positive rate of drug resistance genes in lung cancer that had undergone chemotherapy increased. Conclusions The results of the study indicate that detection of P170 and GSTpi in cancer tissues has important guiding significance for the treatment of lung cancer. It should also be emphasized that chemotherapy for lung cancer should pay special attention to standardization.